A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Identity of Directors, Senior Management and Advisers A. Directors and Senior Management Not applicable. B. Advisers Not applicable. C. Auditors Not applicable.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 30.6B | 30.6B | 28.1B | 28.6B | 27.2B | 29.0B |
| Net Income | 723M | 723M | 949M | 2.2B | 1.8B | 3.4B |
| EPS | $0.23 | $0.23 | $0.31 | $0.73 | $0.57 | $1.10 |
| Free Cash Flow | 5.7B | 5.7B | 3.6B | 5.9B | 7.6B | 8.2B |
| ROIC | 2.5% | 2.5% | 6.4% | 24.2% | 19.7% | 12.4% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.08 | 0.08 | 0.05 | - | - | - |
| Dividends/Share | $0.64 | $0.64 | $0.61 | $0.64 | $0.70 | $0.83 |
| Operating Income | 1.9B | 1.9B | 1.0B | 3.4B | 3.1B | 4.3B |
| Operating Margin | 6.3% | 6.3% | 3.6% | 12.0% | 11.5% | 14.8% |
| ROE | 1.6% | 1.5% | 2.1% | - | - | - |
| Shares Outstanding | 3,154M | 3,154M | 3,102M | 3,078M | 3,094M | 3,087M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 19.2B | 31.0B | 29.0B | 27.2B | 28.6B | 28.1B | 30.6B | 30.6B |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 3.4B | 4.6B | 4.1B | 4.0B | 4.5B | 4.8B | 4.9B | 4.9B |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | 1.5B | 626M | 4.3B | 3.1B | 3.4B | 1.0B | 1.9B | 1.9B |
| Op. Margin | 7.7% | 2.0% | 14.8% | 11.5% | 12.0% | 3.6% | 6.3% | 6.3% |
| Net Income | 1.2B | 417M | 3.4B | 1.8B | 2.2B | 949M | 723M | 723M |
| Net Margin | 6.4% | 1.3% | 11.8% | 6.4% | 7.9% | 3.4% | 2.4% | 2.4% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | 5.5% | 1.6% | 12.4% | 19.7% | 24.2% | 6.4% | 2.5% | 2.5% |
| ROE | 3.8% | N/A | N/A | N/A | N/A | 2.1% | 1.5% | 1.6% |
| ROA | N/A | 1.1% | 9.6% | 14.5% | 18.7% | 1.7% | 0.7% | 0.8% |
| Cash Flow | ||||||||
| Op. Cash Flow | 3.0B | 6.3B | 9.2B | 8.6B | 6.9B | 4.7B | 7.1B | 7.1B |
| Free Cash Flow | 2.3B | 5.1B | 8.2B | 7.6B | 5.9B | 3.6B | 5.7B | 5.7B |
| Owner Earnings | 740M | 811M | 4.1B | 4.1B | 2.2B | -77M | 2.0B | 2.0B |
| CapEx | 712M | 1.2B | 1.0B | 941M | 998M | 1.2B | 1.3B | 1.3B |
| Maint. CapEx | 2.3B | 5.5B | 5.1B | 4.5B | 4.7B | 4.8B | 5.1B | 5.1B |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 2.3B | 5.5B | 5.1B | 4.5B | 4.7B | 4.8B | 5.1B | 5.1B |
| CapEx/OCF | 23.6% | 19.0% | 11.0% | 11.0% | 14.4% | 24.5% | 19.0% | 19.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 1.3B | 2.7B | 2.6B | 2.2B | 2.0B | 1.9B | 2.0B | 2.0B |
| Dividend Yield | 4.0% | 5.1% | 5.4% | 5.3% | 4.4% | 4.6% | 4.5% | 3.6% |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | -596M | 1.1B | 1.1B |
| Cash & Equiv. | 6.4B | 6.0B | 8.8B | 6.5B | 3.8B | 3.0B | 2.6B | 2.6B |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 3.7B |
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | 0.05 | 0.08 | 0.08 |
| Interest Coverage | 4.7 | 0.5 | 4.4 | 3.8 | 4.5 | 1.5 | 2.5 | 2.5 |
| Equity | 47.5B | N/A | N/A | N/A | N/A | 47.9B | 46.4B | 46.4B |
| Total Assets | N/A | 39.3B | 35.4B | 12.1B | 12.0B | 99.4B | 95.3B | 95.3B |
| Total Liabilities | N/A | N/A | N/A | N/A | N/A | 51.6B | 48.9B | 48.9B |
| Intangibles | N/A | 39.3B | 35.4B | N/A | N/A | 35.6B | 35.6B | 35.6B |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | 9.2B | 7.9B | 7.9B |
| Working Capital | N/A | N/A | N/A | N/A | N/A | -531M | -787M | -787M |
| Current Assets | N/A | N/A | N/A | N/A | N/A | 192M | 106M | 106M |
| Current Liabilities | N/A | N/A | N/A | N/A | N/A | 723M | 893M | 893M |
| Per Share Data | ||||||||
| EPS | 0.65 | 0.14 | 1.10 | 0.57 | 0.73 | 0.31 | 0.23 | 0.23 |
| Owner EPS | 0.39 | 0.26 | 1.32 | 1.33 | 0.72 | -0.02 | 0.63 | 0.63 |
| Book Value | 25.09 | N/A | N/A | N/A | N/A | 15.44 | 14.71 | 14.71 |
| Cash Flow/Share | 1.59 | 2.05 | 2.97 | 2.77 | 2.25 | 1.52 | 2.24 | 1.84 |
| Dividends/Share | 0.69 | 0.87 | 0.83 | 0.70 | 0.64 | 0.61 | 0.64 | 0.64 |
| Shares Out. | 1.9B | 3.1B | 3.1B | 3.1B | 3.1B | 3.1B | 3.2B | 3.2B |
| Valuation | ||||||||
| P/E Ratio | 28.4 | 125.2 | 11.5 | 25.4 | 18.2 | 42.4 | 68.2 | 77.7 |
| P/FCF | 15.3 | 10.2 | 4.8 | 5.8 | 6.9 | 11.3 | 8.6 | 9.8 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | 39.3 | 26.2 | 29.7 |
| Price/Book | 0.7 | N/A | N/A | N/A | N/A | 0.8 | 1.1 | 1.2 |
| Price/Sales | 1.7 | 1.7 | 1.6 | 1.5 | 1.6 | 1.5 | 1.5 | 1.8 |
| FCF Yield | 6.5% | 9.8% | 20.7% | 17.1% | 14.5% | 8.9% | 11.6% | 10.2% |
| Market Cap | 35.2B | 52.2B | 39.3B | 44.6B | 41.0B | 40.2B | 49.4B | 56.2B |
| Avg. Price | 17.46 | 16.82 | 15.45 | 13.28 | 14.51 | 13.32 | 14.39 | 17.82 |
| Year-End Price | 18.57 | 16.98 | 12.74 | 14.42 | 13.31 | 12.97 | 15.65 | 17.82 |
TAKEDA PHARMACEUTICAL CO LTD passes 4 of 9 quality checks, suggesting mixed fundamentals.
TAKEDA PHARMACEUTICAL CO LTD trades at 80.7x trailing earnings, compared to its 15-year median P/E of 26.9x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 10.2x vs a median of 8.6x. The company's 5-year average ROIC is 13.1%. Total shareholder yield (dividends) is 3.6%. At current prices, the estimated annualized return to fair value is +4.1%.
TAKEDA PHARMACEUTICAL CO LTD (TAK) has a current P/E ratio of 80.7, compared to its historical median P/E of 26.9. The stock is currently considered Expensive based on its historical valuation range.
TAKEDA PHARMACEUTICAL CO LTD (TAK) has a 5-year average return on invested capital (ROIC) of 13.1%. This indicates solid capital allocation.
TAKEDA PHARMACEUTICAL CO LTD (TAK) has a market capitalization of $56.2B. It is classified as a large-cap stock.
Yes, TAKEDA PHARMACEUTICAL CO LTD (TAK) pays a dividend with a trailing twelve-month yield of 3.60%.
Based on historical P/E analysis, TAKEDA PHARMACEUTICAL CO LTD (TAK) appears expensive. The current P/E of 80.7 is 200% above its historical median of 26.9. The estimated fair value CAGR (P/E method) is -3.5%.
TAKEDA PHARMACEUTICAL CO LTD (TAK) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
TAKEDA PHARMACEUTICAL CO LTD (TAK) reported annual revenue of $30.6 billion in its most recent fiscal year, based on SEC EDGAR filings.
TAKEDA PHARMACEUTICAL CO LTD (TAK) has a net profit margin of 2.4%. This is a modest margin.
TAKEDA PHARMACEUTICAL CO LTD (TAK) generated $5.7 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
TAKEDA PHARMACEUTICAL CO LTD (TAK) has a debt-to-equity ratio of 0.08. This indicates a conservatively financed balance sheet.
TAKEDA PHARMACEUTICAL CO LTD (TAK) reported earnings per share (EPS) of $0.23 in its most recent fiscal year.
TAKEDA PHARMACEUTICAL CO LTD (TAK) has a return on equity (ROE) of 1.5%. This indicates moderate shareholder returns.
The Ledger Terminal provides 7 years of financial data for TAKEDA PHARMACEUTICAL CO LTD (TAK), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
TAKEDA PHARMACEUTICAL CO LTD (TAK) has a book value per share of $14.71, based on its most recent annual SEC filing.
No recent press releases.